Myeloid-related protein 8/14 complex describes microcirculatory alterations in patients with type 2 diabetes and nephropathy by Burkhardt, Klaus et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Cardiovascular Diabetology
Open Access Original investigation
Myeloid-related protein 8/14 complex describes microcirculatory 
alterations in patients with type 2 diabetes and nephropathy
Klaus Burkhardt1, Sonja Schwarz2, Chengrui Pan2, Felix Stelter3, 
Konstantin Kotliar4, Maxilian Von Eynatten2, Daniel Sollinger2, Ines Lanzl2, 
Uwe Heemann2 and Marcus Baumann*2
Address: 1Nephrological Clinic Weissenburg, 91781 Weissenburg, Germany, 2Department of Nephrology, Technical University Munich, 
Ismaningerstr. 22, 81675 Munich, Germany, 3Labor Schottdorf MVZ, 86105 Augsburg, Germany and 4Department of Ophthalmology, Technical 
University Munich, Ismaningerstr. 22, 81675 Munich, Germany
Email: Klaus Burkhardt - praxis-dr-burkhardt@t-online.de; Sonja Schwarz - sonja-schwarz@freenet.de; Chengrui Pan - chengruipan@gmail.com; 
Felix Stelter - labor@schottdorf.de; Konstantin Kotliar - Kotliar@lrz.tu-muenchen.de; Maxilian Von Eynatten - Maximilian.eynatten@lrz.tu-
muenchen.de; Daniel Sollinger - Daniel-sollinger@lrz.tu-muenchen.de; Ines Lanzl - ines.lanzl@lrz.tu-muenchen.de; 
Uwe Heemann - uwe.heemann@lrz.tum.de; Marcus Baumann* - marcus.baumann@lrz.tum.de
* Corresponding author    
Abstract
Background: Inflammation contributes to cardiovascular complications in type 2 diabetes, which are
often characterized by microvascular alterations. We investigated whether myeloid-related protein 8/14
complex (MRP8/14) secreted by transmigrating monocytes and granulocytes may represent a biomarker
for microvascular alterations in patients with type 2 diabetes and nephropathy.
Methods: MRP8/14 was measured in 43 patients with type 2 diabetes and nephropathy. Additionally, the
inflammatory markers Interleukin-6 (IL-6), Tumor necrosis factor-α (TNF-α) and C-reactive protein
(CRP) were quantified. To detect microvascular alterations proteinuria and retinal vessel caliber were
used as classical and novel marker, respectively. Proteinuria was quantified by protein-creatinine ratio
(PCR); retinal vessel caliber was quantified after retina photography on digitalized retina pictures.
Results: MRP8/14 was positively associated with inflammation (r = 0.57), proteinuria (r = 0.40) and retinal
arterial caliber (r = 0.48). Type 2 diabetic patients with MRP8/14 values above the median of 5.8 μg/ml
demonstrated higher proteinuria and larger retinal artery caliber than patients with MRP8/14 values below
the median (logPCR: -0.51 ± 0.52 versus -0.96 ± 0.46, P < 0.01; retinal artery lumen (μm): 178.3 ± 14.1
versus 162.7 ± 14.9 P < 0.01). Both groups did not differ with regard to metabolic factors and blood
pressure. MRP8/14 was an independent predictor of retinal artery caliber in multivariate stepwise
regression analysis (  = 0.607) and was positively associated with IL-6 (r = 0.57, P < 0.001) and TNF-α (r =
0.36, P < 0.05).
Conclusion: MRP8/14 – a marker for transendothelial migration – describes not only the state of
inflammation in diabetic nephropathy, but additionally the degree of microvascular alterations in the
glomerular and retinal bed. Therefore, MRP8/14 may be a potentially selective novel biomarker for
microcirculatory defects in diabetic nephropathy.
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Introduction
Chronic inflammation contributes to type 1 and type 2
diabetes mellitus and is involved in the development of
cardiovascular complications [1,2]. Microvascular com-
plications, which are largely defined by the presence and
degree of proteinuria, are associated with inflammation
[3]. In the case of diabetic nephropathy proteinuria and
systemic inflammation define the cardio-vascular risk [4].
It would be interesting to correlate these changes to the
microvasculature.
Retinal vessels represent a direct non-invasive measure-
ment of vascular lumen diameter on the level of resistance
arteries, hence the microcirculatory level [5]. In this
respect an enlarged retinal arteriolar and venular caliber is
related to diabetes and systemic inflammation [6,7]. The
dilation of the retinal vessels has been attributed to an
increased production of nitric oxide as a result of up-regu-
lated nitric oxide synthase messenger RNA, secondary to
release of cytokines such as IL-1 and TNF-α [8].
Apart from these direct effects of inflammatory markers
on the microcirculation in diabetic nephropathy, little is
known about the contribution of inflammation-initiated
transmigration of monocytes through the arteriolar wall.
We hypothesize that the myeloid-related protein 8/14
complex (MRP8/14), a marker of monocyte and neu-
trophil activation [9], predicts microvascular changes at
an early stage. MRP8/14, also termed calprotectin, leuko-
cyte protein L1 complex or cystic fibrosis antigen, is a het-
erodimer of two calcium-binding proteins (S100A8 and
S100A9, also referred to as MRP8 and MRP14, or calcran-
ulin A and B involved in calcium-dependent signaling,
cell differentiation, cell cycle progression, and cytoskele-
ton-membrane interactions [10]. MRP8 and MRP14 are
primarily expressed in cells of myeloid origin, particularly
in monocytes and neutrophils [11]. Upon phagocyte acti-
vation, MRP8 and MRP14 form the MRP8/14 complex,
which translocates to the cytoskeleton and plasma mem-
brane, where it is secreted [12,13]. This is an early event
during transendothelial migration and thus represents an
interaction of MRP-expressing neutrophils and mono-
cytes with endothelium [14]. Therefore we further
hypothesize that systemic inflammation in diabetic neph-
ropathy results in an increased transendothelial migratory
activity of monocytes and neutrophils and hence microv-
ascular changes in the glomerular and retinal vascular
bed. It is the aim of this study to investigate in patients
with type 2 diabetes and nephropathy whether the degree
of proteinuria and retinal arteriolar lumen diameter are
associated with markers of inflammation and endothelial
transmigration. Furthermore we describe one patient
demonstrating reduction of MRP8/14 and proteinuria
under TNF-blockade, potentially mirroring the patho-
physiological relevance of MRP8/14.
Methods
Forty-three patients with type 2 diabetes with nephropa-
thy were recruited from the nephrological clinic Weissen-
burg. In the entire cohort, the simplified MDRD
(Modification of Diet in Renal Disease) equation was
used to estimate the glomerular filtration rate (eGFR (ml/
min/1.73 m2) = 186 × (serum creatinine (mg/dl))-1.154 ×
(age)-0.203 × (0.742 if female) × (1.212 if black)). Proteinu-
ria was quantified in spot urine by measurement of the
protein-creatinine ratio (PCR). PCR was log-transformed
to better approximate normal distributions. Additionally,
cardiometabolic risk factors were evaluated and biological
parameters measured, according to the recommendations
of the American and European clinical practice guidelines.
Anti-diabetic and anti-hypertensive medication was
recorded including insulin-therapy, oral anti-diabetics,
and the total number of antihypertensive drugs including
differentiation of inhibitors of the renin-angiotensin sys-
tem (RAS) or calcium channel blockers. The research has
been carried out in accordance with the Declaration of
Helsinki (2000) of the World Medical Association, and
has been approved by the local Ethics Committee of the
institution. Written informed consent was obtained from
each patient after full explanation of the purpose, nature
and risk of all procedures. One trained person measured
anthropometric characteristics. For ≥3 hours before the
examination, the participants refrained from heavy exer-
cise, smoking, and alcohol or caffeine-containing bever-
ages. The body mass index was weight in kilograms
divided by height in meters squared. Venous blood sam-
ples, collected after overnight fasting, were analyzed by
standard automated methods for lipids and blood glu-
cose. Diabetes mellitus was defined as a fasting blood glu-
cose level of at least 7.0 mmol/l or as the use of
antidiabetic drugs.
IL-6, TNF-α (R&D Systems, Minneapolis, MN, USA) and
MRP8/14 (Bühlmann Laboratories, Schönenbuch, Swit-
zerland), were determined by commercially available
ELISA using serum samples.
Measurement of retinal vessels
One trained person performed the retina measurements.
Methods used to measure and summarize retinal vessel
diameters from digitized photographs followed a stand-
ardized protocol described elsewhere [15]. In brief, two
30° color retinal photographs of the left and two photo-
graphs of the right eye were taken at baseline. They were
digitized by a high resolution scanner with standard set-
tings (IMEDOS, Jena, Germany). Graders masked to the
characteristics of participants used a computer program to
measure diameters of all arterioles and venules in a speci-
fied zone surrounding the optic disc. These measurements
were combined into summary indices – the central retinal
arteriolar and venular equivalents – which represented theCardiovascular Diabetology 2009, 8:10 http://www.cardiab.com/content/8/1/10
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average arteriolar (CRAE) and venular (CRVE) diameters
of that eye, respectively. These were additionally expressed
as the retinal arteriolar-venular ratio (AVR). The ratio
compensated for possible magnification differences
between eyes, and an AVR of 1 indicated that arteriolar
diameters were, on average, the same as venular diameters
in that eye, while a smaller ratio suggested narrower arte-
rioles. The AVR reflects the mean of the four photographs.
Aortic Pulse Wave Velocity
Aortic pulse wave velocity (aPWV) was assessed by sensi-
tive transducers and the results were analysed using the
Complior program (Complior, Artech Medical, Pantin,
France) [16]. First, patients rested in the supine position
for 5 min. Brachial blood pressure was measured by an
oscillometric device (Omron, Japan). Pressure-sensitive
sensors were placed on the right carotid, radius and femo-
ral artery. The distance between two sites (carotid-radius,
carotid-femoral) was estimated automatically according
to the body height of the patients. The time difference was
determined from the delay of starting phase of the first
wave between carotid and another site ("foot-to-foot
method"). Aortic PWV was calculated by dividing the dis-
tance by the time difference. At least 10 signals were
obtained twice and averaged to the results. In the case of
an intra-patient variance of more than 10%, a third meas-
urement was performed. Data were collected by a single
observer (P.C.R.). The intra-observer coefficient of varia-
tion for carotid-femoral (C-F) PWV was 2.5%.
24-hour ambulatory blood pressure measurements
Programmed and validated blood pressure devices
(model 90207; Spacelabs Medical, Issaquah, Washington,
USA) were used to obtain blood pressure recordings at
intervals of 20 min from 0700 to 2300 h, and every 30
min from 2300 to 0700 h. We calculated the within-sub-
ject 24-h means of the ambulatory measurements with
weights according to the time interval between successive
readings [17].
Statistical analysis
Data are expressed as means ± SD or percentages. The
unpaired t-test, Mann-Whitney U-test or χ2-test were used
for comparing the upper and lower MRP8/14 median
group. Within the cohort, multiple linear regression anal-
ysis was used to evaluate which factors were independ-
ently associated with retinal arteriolar diameter. Data
were analyzed using SPSS software (version 14.0). All tests
were two-sided and a P-value < 0.05 was considered sig-
nificant.
Results
Baseline characteristics
Patients with diabetic nephropathy and proteinuria are
characterized in Table 1. They were stratified according to
the median of the myeloid-related protein complex to
assess whether MRP8/14 affects cardiovascular and meta-
bolic characteristics (MRP8/14: median: 5.8 μg/ml, 25th
percentile: 3.2, 75th percentile: 11.8, Table 1).
Anthropometric data and renal function were comparable
between the groups. The distribution according to the
median of MRP8/14 did not lead to difference in HbA1c
and lipid profile. The use of insulin therapy was signifi-
cantly higher in patients with higher MRP8/14 values (50
versus 17%, P < 0.05). The number of antihypertensive
drugs and the use of calcium channel blocker (data not
shown) and RAS-blocker were similar in both groups.
MRP8/14 values had no influence on ambulatory blood
pressure and arterial stiffness. In contrast, MRP8/14 values
above the median correlated with microvascular altera-
tions including increased proteinuria and enlarged retinal
arterioles. Proinflammatory characteristics were promi-
nent in patients with MRP8/14 values above the median.
Association of inflammation and microcirculatory aspects
Patients with diabetic nephropathy and proteinuria had a
positive association between the degree of proteinuria and
inflammation, although restricted to IL-6 (r = 0.39, P <
0.05, Figure 1). Other inflammatory parameters such as
TNF-α and CRP were not significantly associated with the
degree of proteinuria.
As second microvascular characteristic the luminal diam-
eters of central retinal arterioles (CRAE) were investigated
and associated with inflammatory markers. Here, IL-6 and
TNF-α were positively associated with the lumen diameter
of CRAE (r = 0.42, P < 0.01 and r = 0.41, P < 0.05).
Association of transmigration, inflammation and 
microcirculatory aspects
MRP8/14 as marker for monocyte transmigration was
positively associated with IL-6 and TNF-α (r = 0.57, P <
0.001 and r = 0.36, P < 0.05, Figure 2). Moreover, MRP8/
14 was positively associated with the degree of proteinuria
(r = 0.40, P < 0.05) and the lumen diameters of CRAE (r =
0.48, P < 0.01).
Multivariable regression models were used to estimate the
partial association between CRAE, inflammatory markers
and MRP8/14 (Table 2). In patients with diabetic neph-
ropathy and proteinuria, IL-6, TNF-α and MRP8/14 were
significantly and independently associated with CRAE
after adjustment for age, gender, BMI, glucose, 24 h SBP,
and eGFR. This association remained significant for
MRP8/14 and CRAE even after further adjustment for IL-
6 and TNF-α.Cardiovascular Diabetology 2009, 8:10 http://www.cardiab.com/content/8/1/10
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Effect of TNF-blockade on MRP8/14 and proteinuria
A 48 year-old male patient with type 2 diabetes and neph-
ropathy a HLA-B27 positive ankylosing spondylarthritis
was diagnosed. Based on the activity of the ankylosing
spondylarthritis a TNF-blockade with etanercept (50 mg/
week s.c.) was initiated. Under this treatment we observed
after 3 month of treatment that MRP8/14 as transmigra-
tory marker decreased from 19.9 μg/ml prior etanercept to
3.2 μg/ml. After one year of treatment MRP8/14 remained
low with 2.2 μg/ml. Secondly, we observed that proteinu-
ria decreased under the TNF-blockade from 378 to 58 mg
protein/g creatinine at 3 month and remained low after
one year of treatment (49 mg protein/g creatinine).
Discussion
Our study demonstrates in patients with type 2 diabetes
and nephropathy that MRP8/14, a marker for transend-
othelial migration of monocytes and neutrophils, may
predict changes in the microvascular bed of glomeruli and
retina beyond inflammation. These changes are for the
glomerular bed the degree of proteinuria and in the retinal
bed an increase of arteriolar lumen caliber. Thus, MRP8/
14 is a potential biomarker for microvascular defects in
patients with diabetic nephropathy which may represent
a pathophysiological relevant feature. Furthermore, these
results implicate a potential deleterious role of increased
arteriolar lumen caliber if associated with inflammation
Table 1: Clinical characteristics of patients with type 2 diabetes and nephropathy as total cohort and grouped according to the median 
of MRP8/14
Characteristics ALL (n = 43) < MRP8/14 median (n = 22) > MRP8/14 median (n = 21)
Age (years) 66.5 ± 12.2 65.2 ± 13.6 67.3 ± 12.0
Gender (% men) 58.1 68.2 47.6
BMI (kg/m2) 31.2 ± 5.9 29.8 ± 3.9 32.3 ± 7.6
Waist circumference (cm) 110.7 ± 15.3 107.1 ± 10.4 114.4 ± 19.1
Smoking (%) 6.9 13.6 0.0
Glycemia (mmol/l) 6.55 ± 1.95 6.64 ± 1.46 6.43 ± 1.86
Hba1c (%) 6.7 ± 0.8 6.7 ± 0.8 6.7 ± 0.7
Cholesterol (mmol/l)
Total 180.2 ± 37.6 171.2 ± 33.6 185.1 ± 38.5
HDL 49.1 ± 13.6 46.4 ± 9.8 51.2 ± 13.2
LDL 100.2 ± 31.6 96.9 ± 28.9 104.1 ± 35.6
Triglyceridemia (mmol/l) 174.9 ± 113.2 175.6 ± 94.8 146.1 ± 88.7
eGFR (ml/min/1.73 m2) 61.3 ± 36.1 66.5 ± 30.0 55.1 ± 44.8
Protein-creatinine ratio (log) -0.76 ± 0.54 -0.96 ± 0.46 -0.51 ± 0.52 **
Insulin therapy (%) 32 17 50 *
RAS-Inhibition (%) 86 91 85
Statin therapy (%) 45 57 35
Cardiovascular
24 h systolic BP (mmHg) 135.6 ± 11.5 134.1 ± 11.6 138.3 ± 11.4
24 h diastolic BP (mmHg) 71.8 ± 10.9 72.6 ± 11.8 68.4 ± 10.0
24 h Pulse pressure (mmHg) 63.8 ± 8.4 62.5 ± 7.7 66.5 ± 8.5
aPWV 11.5 ± 3.1 11.7 ± 3.3 11.4 ± 2.9
CRAE (μm) 169.1 ± 16.0 162.7 ± 14.9 178.3 ± 14.1 **
CRVE (μm) 219.8 ± 22.3 217.4 ± 26.7 221.3 ± 19.2
AVR 0.818 ± 0.085 0.796 ± 0.077 0.856 ± 0.082 *
Inflammation and transmigration
IL-6 (pg/ml) 1.01 ± 1.09 0.59 ± 0.31 1.70 ± 1.52 *
TNF-α (pg/ml) 6.95 ± 4.52 5.05 ± 3.62 9.10 ± 5.27 *
CRP (mg/dl) 9.5 ± 13.2 5.3 ± 6.5 15.5 ± 19.1
MRP8/14 (μg/ml) 8.53 ± 6.92 3.98 ± 1.04 14.08 ± 7.73 ***
Values represent mean ± SD or percentages (%).
BMI: body mass index, eGFR: estimated glomerular filtration rate, HDL: High-density lipoprotein, LDL: Low-density lipoprotein, IL-6: Interleukin-6, 
TNF-α: Tumor necrosis factor-α, MRP8/14: myeloid-related protein complex, CRP: C-reactive peptide, BP: blood pressure, RAS: renin-angiotensin 
system, AVR: arteriolar-venular ratio, CRAE: central retinal arteriolar equivalent, CRVE: central retinal venular equivalent *p < 0.05, **p < 0.01 ***p 
< 0.001 versus < MRP8/14 medianCardiovascular Diabetology 2009, 8:10 http://www.cardiab.com/content/8/1/10
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and transmigration in patients with diabetic nephropa-
thy.
Diabetic nephropathy is characterized by proteinuria and
low-grade systemic inflammation [18]. Both factors have
been associated with microvascular complications [1] and
hence predict cardiovascular outcome [2]. In this context,
MRP8/14 was in our study positively associated with
Interleukin-6 as marker for systemic inflammation [19]
and TNF-α as marker for metabolic driven inflammation
[20] in patients with diabetic nephropathy. This is of rele-
vance as sequential migration of neutrophils is stimulated
by TNF-α induced inflammation and can be reduced by
inhibition of Interleukin-6 secretion [21]. Thus, a causal
relationship with the option to modulate the degree of
microvascular damage may be suggested. Besides, the
degree of proteinuria and retinal arteriolar caliber as con-
ventional and novel microvascular factors were positively
associated with MRP8/14. Thus, systemic MRP8/14 values
seem to reflect not only the grade of inflammation, but
also may define the microcirculation as the place of
action. The microcirculatory action is not restricted to one
organ as glomerular and retinal effects are observed.
Moreover, Alwegg et al. demonstrated the local coronary
release of MRP8/14 in acute coronary syndrome [14].
Thus we suggest that the MRP8/14 activity reflects a gen-
eralized microcirculatory effect of increased transendothe-
lial migration. In contrast, there is a lack of association
between arterial stiffness measured by the gold standard
of aortic PWV and MRP8/14. This suggests that no domi-
Bivariate correlations of Interleukin-6 (IL-6) and TNF-α with proteinuria and retinal artery caliber in patients with type 2 diabe- tes and nephropathy: A) IL-6 and proteinuria, B) IL-6 and retinal artery caliber, C) TNF-α and proteinuria and D) TNF-α and  retinal artery caliber Figure 1
Bivariate correlations of Interleukin-6 (IL-6) and TNF-α with proteinuria and retinal artery caliber in patients 
with type 2 diabetes and nephropathy: A) IL-6 and proteinuria, B) IL-6 and retinal artery caliber, C) TNF-α and 
proteinuria and D) TNF-α and retinal artery caliber. We observed significant positive correlations for A) r = 0.39, B) r 
= 0.42 and D) r = 0.41. All correlations are given as calculated by Spearman correlation coefficient.Cardiovascular Diabetology 2009, 8:10 http://www.cardiab.com/content/8/1/10
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nant effect of transmigration is present in the context of
the macrocirculation. This further emphasizes MRP8/14
as a novel and potentially selective marker for microcircu-
latory effects in diabetic nephropathy.
Studies in diabetic nephropathy are fraught with diffi-
culty, given the recognized associations with hypertension
and dyslipidemia, both of which are known to influence
the microcirculation [22]. It is important to notice that
our cohort after stratification according to MRP8/14
remains comparable for the lipid profile and 24-hour
blood pressure measurement. Therefore, it is unlikely that
MRP8/14 as marker for transendothelial migration is
largely influenced by these two factors. Hence, enhanced
MRP8/14 may describe a pathomechanism independent
of hypertension and dyslipidemia in patients with dia-
betic nephropathy.
Furthermore, we describe one patient in whom TNF-
blockade was initiated due to an ankylosing spondylar-
thritis. In this patient MRP8/14 and proteinuria measure-
ments were available before and during treatment
covering a period of 18 month. The measurements
showed a decrease both of transmigration and proteinuria
as marker for microcirculatory damage. These observa-
tions may be interpreted as pathophysiological relevant
Bivariate correlations of MRP8/14 with A) Interleukin-6 (IL-6) and B) TNF-α as inflammatory marker and C) with proteinuria  and D) retinal artery caliber as microcirculatory marker in patients with type 2 diabetes and nephropathy Figure 2
Bivariate correlations of MRP8/14 with A) Interleukin-6 (IL-6) and B) TNF-α as inflammatory marker and C) 
with proteinuria and D) retinal artery caliber as microcirculatory marker in patients with type 2 diabetes and 
nephropathy. We observed significant positive correlations for A) r = 0.57, B) r = 0.36, C) r = 0.40 and D) r = 0.48. All cor-
relations are given as calculated by Spearman correlation coefficient.Cardiovascular Diabetology 2009, 8:10 http://www.cardiab.com/content/8/1/10
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link between inflammation, transmigration and microcir-
culatory alterations. However, in the future this clearly
needs to be investigated in detail.
Is a larger retinal arteriolar caliber in patients with diabetic
nephropathy deleterious? In patients with type 2 diabetes
the myogenic responsiveness is impaired. Schofield et al.
demonstrated in pressure myograph experiments using
resistance arteries of type 2 diabetic subjects that above a
luminal pressure of 50 mmHg no reactive contractility
was present whereas control subjects gave a blood pres-
sure dependent myogenic response [22]. As a conse-
quence wall stress may rise resulting in vascular
hypertrophy [23].
In our cohort of patients with diabetic nephropathy high
MRP8/14 values are associated with larger arteriolar
lumen caliber, which may reflect a failure to autoregulate
blood flow efficiently [24]. This may increase high blood
pressure flow to target organs, effecting downstream dam-
age, as determined in our patients by increased proteinu-
ria particularly in subjects with elevated MRP8/14 levels.
The failure of blood flow autoregulation may result in
enlarged preglomerular afferent arterioles. This increases
intraglomerular pressure with the consequence of pro-
teinuria [25]. Secondly, capillary transmigration may
directly damage podocytes thereby aggregating capillary
leakage which corresponds with proteinuria [26]. These
options raise the new speculation whether the defective
myogenic response observed in type 2 diabetes is not only
regulated by metabolic factors [27,28], but is also related
to the degree of local inflammation and transmigration.
In summary, we demonstrate that MRP8/14 as marker for
transendothelial migration describes not only the state of
inflammation in diabetic nephropathy, but additionally
the degree of microvascular alterations. Therefore, MRP8/
14 is a potentially selective novel biomarker for microcir-
culatory defects, which may play a pathophysiological rel-
evant role.
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